Bafilomycin A1 enhances NLRP3 inflammasome activation in human monocytes independent of lysosomal acidification by Yu, Shi et al.
Bafilomycin A1 enhances NLRP3 inflammasome activation
in human monocytes independent of lysosomal
acidification
Shi Yu1,2, Jack Green1,2 , Rose Wellens1,2, Gloria Lopez-Castejon3,2 and David Brough1,2
1 Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health,
Manchester Academic Health Science Centre, University of Manchester, UK
2 Lydia Becker Institute of Immunology and Inflammation, University of Manchester, UK
3 Manchester Collaborative Centre for Inflammation Research (MCCIR), Division of Infection, Immunity & Respiratory Medicine, School of
Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, UK
Keywords
alternative NLRP3 inflammasome; caspase
1; cytokine; immune cell; immunology;
inflammasome; inflammation; interleukin 1;
monocyte; NLRP3
Correspondence
D. Brough, Division of Neuroscience and
Experimental Psychology, School of
Biological Sciences, Faculty of Biology,
Medicine and Health, Manchester Academic
Health Science Centre, University of
Manchester, AV Hill Building, Oxford Road,
Manchester M13 9PT, UK
Tel: +44 (0)161 275 5039
E-mail: david.brough@manchester.ac.uk
(Received 2 March 2020, revised 12
October 2020, accepted 2 November 2020)
doi:10.1111/febs.15619
The release of interleukin (IL)-1b from primary human monocytes in
response to extracellular LPS occurs through the NACHT, LRR and PYD
domains-containing protein 3 (NLRP3) inflammasome. In primary mono-
cytes, in response to LPS, NLRP3 inflammasome activation is character-
ized by an independence of K+ efflux and ASC speck formation and has
been termed the ‘alternative’ pathway. Here, we report that pharmacologi-
cal inhibition of V-ATPase with bafilomycin A1 exacerbated LPS-induced
NLRP3 inflammasome activation in primary human monocytes. Inhibition
of V-ATPase in the presence of extracellular LPS led to NLRP3-depen-
dent, K+ efflux-independent, ASC oligomerization and caspase-1 activation.
Although V-ATPases are required for lysosomal acidification, we found
that acidic lysosomal pH and protease activity were dispensable for this
altered response, suggesting that V-ATPase inhibition triggered alternative
signalling events. Therefore, V-ATPases may serve additional roles during
NLRP3 inflammasome activation in primary human monocytes.
Introduction
Inflammasomes serve as the major site for activation
for caspase-1 and pro-inflammatory cytokines IL-1b
and IL-18. Understanding the regulation of IL-1b is
particularly important as its dysregulation is strongly
associated with inflammatory diseases [1]. There are a
number of different types of inflammasome. A com-
monly studied inflammasome and one known to con-
tribute to inflammation within multiple diseases is
formed by the NOD-like receptor (NLR) family
member NLRP3 (NACHT, LRR and PYD domains-
containing protein 3). Due to its association with
diverse diseases, there is major interest in understand-
ing the regulation of the NLRP3-IL-1b pathway [2].
There are several suggested pathways for the activa-
tion of NLRP3, the best studied of which is termed
the ‘canonical’ pathway, reported mainly in macro-
phages, and which requires two signals. The initial
stimulus is a priming signal, where pathogen-
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associated molecular patterns (PAMPs), or damage-as-
sociated molecular patterns (DAMPs), are sensed by
PRRs, which then transduce an intracellular signal
resulting in increased expression of NLRP3, and an
inactive precursor pro-IL-1b. The second stage of
canonical NLRP3 inflammasome activation occurs
when a primed cell receives an additional stimulus,
often causing K+ efflux from the cell, which triggers a
change in the conformation of NLRP3 that allows it
to bind to an adaptor protein called apoptosis-associ-
ated speck-like protein containing a CARD (ASC).
The NLRP3-ASC interaction drives the polymerization
of ASC into what is known as the ASC speck. The
cysteine protease caspase-1 is then recruited to, and
activated at, the ASC speck. The whole complex is
known as the NLRP3 inflammasome [2]. Activated
caspase-1 at the inflammasome complex then cleaves
pro-IL-1b to a mature IL-1b molecule, which is then
secreted from the cell via gasdermin D (GSDMD)
pores to induce an inflammatory response [3,4].
GSDMD pores can also drive pyroptosis which leads
to the release of inflammasome complexes and addi-
tional DAMPs [5,6].
In contrast to macrophages, in primary human
monocytes a singular PAMP stimulus, for example
extracellular lipopolysaccharide (LPS), is sufficient to
trigger NLRP3-dependent activation of caspase-1 and
IL-1b secretion [7–9]. In human monocytes, LPS-in-
duced IL-1b release occurs with no detectable ASC
oligomerization, is independent of K+ efflux, and has
been termed the ‘alternative’ NLRP3 inflammasome
[8]. LPS-induced NLRP3 inflammasome activation in
human monocytes occurs in the absence of cell death
and can further respond to NLRP3 agonists [8], unlike
noncanonical NLRP3 inflammasome activation driven
by intracellular LPS, caspase-4, and GSDMD [10]. It
is important to further our understanding of the
NLRP3 inflammasome in human blood, in order to
explore disease models associated with acute infection
such as sepsis or chronic inflammatory conditions such
as atherosclerosis. Here we discovered that vacuolar
ATPase (V-ATPase) inhibitors enhanced activity of
the NLRP3 inflammasome in primary human mono-
cytes, and the effect was independent of an effect on
lysosomal pH. The V-ATPase is a multi-subunit pro-
tein complex that regulates many cellular processes
[11]. Well known for a regulatory role on lysosomal
pH and degradation of autophagic cargo, the V-
ATPase has additional roles in regulating protein sort-
ing and cellular homeostasis [12,13]. Thus understand-
ing V-ATPase-dependent regulation of NLRP3 will
lead to new insights into the signalling pathways coor-
dinating inflammatory responses.
Results
Inhibition of V-ATPase regulates ASC
oligomerization in primary human monocytes
Primary human monocytes were collected by positive
selection for cell surface CD14 from peripheral blood
mononuclear cells (PBMCs) obtained from healthy
human donors. Fresh monocytes were immediately
challenged with LPS (1 µgmL1, 18 h). Western blot-
ting of the nonidet P-40 (NP-40)-insoluble fraction
cross-linked with disuccinimidyl suberate (DSS)
showed that LPS alone caused minimal ASC
oligomerization (Fig. 1A). Western blotting of the sol-
uble fraction confirmed that LPS alone activated cas-
pase-1, as evidenced by the presence of the caspase-1
p10 subunit (Fig. 1A). Treatment with a V-ATPase
inhibitor bafilomycin A1 (100 nM, BafA) [14] at the
same time as LPS, caused extensive ASC oligomeriza-
tion and increased caspase-1 activation, while addition
of bafilomycin A1 alone did not activate caspase-1
(Fig. 1A). Bafilomycin A1 is an inhibitor of lysosomal
acidification, where it is known to prevent the degra-
dation of autophagic vacuoles [15,16]. Indeed,
increased levels of the lipidated microtubule-associated
proteins 1A/1B light chain 3B (LC3B), a marker of
the autophagosome membrane [17], were observed
after bafilomycin A1 treatment indicating that lysoso-
mal degradation was inhibited (Fig. 1A). The impor-
tance of the V-ATPase for the regulation of the
NLRP3 pathway was confirmed by treating primary
human monocytes with LPS, plus and minus bafilo-
mycin A1, and another specific inhibitor of the V-
ATPase, concanamycin A (100 nM, ConA) [18]. Both
bafilomycin A1 and concanamycin A increased levels
of active caspase-1 p20 and lipidated LC3B in the
presence of LPS (Fig. 1B). The increased ASC
oligomerization observed by western blot above was
mirrored by immunocytochemistry for ASC where
ASC specks were revealed by LPS and bafilomycin
A1 co-treatment of monocytes using wide-field fluores-
cence microscopy (Fig. 1C). To rule out proteasomal
degradation of NLRP3 accounting for changes in cas-
pase-1 activation we used epoxomicin, a proteasomal
chymotrypsin activity inhibitor, which had no effect
on LPS-induced caspase-1 activation, but strongly
inhibited pro-IL-1b expression (Fig. 1D). As a result
of exacerbated inflammasome ASC speck formation
and caspase-1 activation, LPS and bafilomycin A1 co-
treatment caused a significant increase in IL-1b secre-
tion from human CD14 monocytes compared to LPS
alone (Fig. 1E). Furthermore LPS and bafilomycin A1
together caused a significant increase in cell death as
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measured by lactate dehydrogenase (LDH) release
(Fig. 1F). LPS-induced release of IL-6, and TNF,
were not affected by bafilomycin A1, although bafilo-
mycin A1 did induce a significant increase in the
release of IL-1a (Fig. 1G-I). IL-1a can also be regu-
lated by the NLRP3 inflammasome [19]. These data
suggest that the effects of bafilomycin A1 could be
specific for the NLRP3 inflammasome and unrelated
to the release of other cytokines.
Effects of V-ATPase inhibition are NLRP3
dependent
To confirm that the increased ASC oligomerization
observed in the presence of LPS and bafilomycin A1
was due to NLRP3, we performed the above experiment
in CD14+ monocytes with LPS plus and minus raised
extracellular K+ (+20 mM KCl) which is known to inhi-
bit the canonical NLRP3 pathway [20]. There was no
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difference in ASC oligomerization, caspase-1 activation,
or LC3B lipidation between LPS and bafilomycin A1
treated cells in the absence or presence of high K+
(Fig. 2A). However, the NLRP3 inflammasome inhibi-
tor MCC950 [21] inhibited the appearance of active cas-
pase-1 in response to LPS, and LPS plus bafilomycin
A1, in CD14+ monocytes confirming that indeed we
were manipulating the NLRP3 pathway (Fig. 2B).
Raised extracellular K+ inhibited nigericin-induced
NLRP3 activation in LPS treated CD14+ primary
monocytes (Fig. 2C), suggesting that bafilomycin A1
may be enhancing the alternative NLRP3 pathway. The
alternative NLRP3 inflammasome, unlike the canonical,
depends on the Toll-like receptor (TLR)-adaptor pro-
tein TRIF [8]. Pretreatment of CD14+ monocytes with a
TRIF inhibitory peptide (TRIFinh, 50 µM) inhibited
caspase-1 activation in response to LPS treatment
(Fig. 2D). Moreover, the TRIF inhibitory peptide also
inhibited caspase-1 activation in response to LPS and
bafilomycin A1 treatment (Fig. 2D). Bafilomycin A1
addition after LPS pretreatment (1 µgmL1, 4 h) did
not enhance nigericin-induced caspase-1 activation in
THP-1 monocytes (Fig. 2E), suggesting that bafilomy-
cin A1 was selectively enhancing the alternative NLRP3
pathway. Bafilomycin A1 also enhanced MCC950-sensi-
tive caspase-1 activation induced by previously
described TLR2 agonists [9], such as the synthetic
Pam3CSK4 (10 µgmL1), peptidoglycan (PGN) from
Staphylococcus aureus (PGN, 20 µgmL1), and
endogenous TLR4 agonist human serum amyloid A
(SAA, 5 µgmL1) in primary human monocytes
(Fig. 2F) showing that the effects of V-ATPase inhibi-
tion were not limited to LPS. Caspase-1 is produced as a
45 kDa pro-form. Activation of pro-caspase-1 generates
firstly a p33 caspase-1 species which is followed by cas-
pase activation and recruitment domain (CARD)
domain linker cleavage leading to p20 and p10
heterodimers [22]. We repeated the experiment with LPS
and bafilomycin A1 in human monocytes in the pres-
ence of a cell-permeable irreversible caspase-1-specific
probe, biotin-YVAD-cmk (bYVAD, 50 lM). After
NLRP3 inflammasome stimulation with LPS, the
bYVAD trapped more caspase-1 in its active p33 form
in the bafilomycin A1 and LPS treated cells, compared
to LPS alone (Fig. 2G). These data suggest caspase-1
activity is enhanced by the presence of the ASC speck.
We were also able to use THP-1 monocytes to study
the NLRP3 dependence of V-ATPase inhibition. Undif-
ferentiated WT and NLRP3 knockout (NLRP3 KO)
THP-1 cells were treated with bafilomycin A1, LPS, or
LPS and bafilomycin A1. In WT, but not NLRP3 KO
THP-1 cells, LPS alone induced robust caspase-1 activa-
tion and this was further enhanced by the presence of
bafilomycin A1 (Fig. 3A). Similar to the primary mono-
cytes, IL-1b release was significantly enhanced in WT
THP-1 cells treated with bafilomycin A1 and LPS, com-
pared to LPS alone, and this was absent in NLRP3 KO
cells (Fig. 3B). The enhanced cell death caused by LPS
and bafilomycin A1 treatment was also NLRP3-depen-
dent as LDH release was inhibited in treated NLRP3
KO THP-1 cells (Fig. 3C). LPS-induced caspase-1 acti-
vation in undifferentiated THP-1 cells was not inhibited
by addition of 20 mM K+, whereas increased caspase-1
activity triggered by nigericin treatment (10 µM) was
inhibited by high extracellular K+ (Fig. 3D). LPS alone,
or LPS plus bafilomycin A1, did not activate caspase-1
in phorbol myristate acetate (PMA) differentiated THP-
1 macrophages (Fig. 3E).
V-ATPase dependent effects on NLRP3 are
independent of lysosomal pH
These data so far would logically point to an inhibi-
tion of lysosomal activity or pH as being responsible
Fig. 1. The V-ATPase regulates the NLRP3 inflammasome in primary CD14+ monocytes. (A) Western blots of DSS cross-linked Nonidet P-
40 (NP-40) insoluble ASC oligomers and NP-40 soluble ASC, pro-caspase-1 (p45), mature caspase-1 (p10), and lipidated LC3B, detected
from human CD14+ monocyte total cell lysates stimulated with LPS (1 µgmL1) plus or minus bafilomycin A1 (BafA, 100 nM) for 18 h
(n = 6). (B) Western blots of mature caspase-1 (p20) and LC3B detected from CD14+ monocyte total lysates (cell lysates + supernatants)
stimulated with BafA (100 nM) or concanamycin A (ConA, 100 nM) plus or minus LPS (1 µgmL1) for 18 h (n = 4). (C) Representative
immunofluorescence images of CD14 + monocytes immunostained for ASC in AlexaFluor 594 (red), with a DAPI (blue) nuclear co-stain after
stimulation with LPS (1 µgmL1) plus and minus BafA (100 nM) for 18 h (scale bar is 25 µM, arrow heads denote ASC specks) (n = 4). (D)
Western blot of mature caspase-1 (p20), pro-IL-1b (p31), mature IL-1b (p17) and b-actin, from human CD14+ monocyte total cell lysate
stimulated with LPS (1 lgmL1) in the presence of V-ATPase inhibitor bafilomycin A1 (BafA, 100 nM) or chymotrypsin inhibitor epoxomicin
(Epo, 100 nM) (n = 3). (E) IL-1b release and (F) cell death measured by ELISA and LDH assay respectively from the supernatants of CD14+
monocytes stimulated with LPS (1 µgmL1) and/or BafA (100 nM) for 18 h (n = 9). (G) IL-6, (H) TNF and (I) IL-1a release measured by
ELISA, from human CD14+ monocyte supernatants stimulated with LPS (1 µgmL1) in the presence or absence of BafA, (100 nM) for 18 h
(n = 9). *P < 0.05, ***P < 0.001; ns, not significantly different determined by a one-way ANOVA with Sidak’s post hoc comparison. Values
shown are the mean  SEM.
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for the effects of bafilomycin A1 on the NLRP3
inflammasome. Indeed addition of bafilomycin A1
abolished lysosomal activity in CD14+ monocytes as
measured by DQ-BSA Red cleavage, a fluorogenic
substrate which measures lysosomal protease activity,
confirming a blockage of pH dependent lysosomal
function (Fig. 4A). Bafilomycin A1 inhibited lysosomal
protease activity in both the absence and presence of
Fig. 2. NLRP3 dependence of the V-ATPase effect in monocytes. (A) Western blots of DSS cross-linked NP-40 insoluble ASC oligomers and
NP-40 soluble ASC, caspase-1 (p20), and LC3B from CD14+ monocyte total cell lysates stimulated with LPS (1 µgmL1) plus and minus
bafilomycin A1 (BafA, 100 nM) and extracellular KCl (20 mM) for 18 h (n = 4). (B) Western blot of mature caspase-1 (p20) from
CD14 + monocyte total cell lysates stimulated with LPS (1 µgmL1) plus and minus BafA (100 nM) supplemented with MCC950 (5 µM) or
extracellular KCl (20 mM) (n = 3). (C) Western blot of mature caspase-1 (p20) from CD14+ monocyte total cell lysate stimulated with LPS
(1 µgmL1) plus and minus BafA (100 nM) or nigericin (Nig, 10 µM) supplemented with extracellular KCl (20 mM) for 18 h. Nigericin was
added at the last hour of stimulation (n = 2). (D) Western blot of caspase-1 (p20) from CD14 + monocyte total cell lysate treated with
control peptide or TRIF blocking peptide (TRIFinh, 50 µM) for 2 h, before stimulation with LPS (1 µgmL1) plus and minus BafA (100 nM) for
18 h (n = 4). (E) Western blot of caspase-1 (p20) from na€ıve or LPS-primed (1 µgmL1, 4 h) THP-1 monocyte total cell lysates preincubated
with or without BafA (100 nM, 15 min) before addition of nigericin (10 µM, 1 h) (n = 4). (F) Upper panel: Western blot of mature caspase-1
(p20), and b-actin, from CD14 + monocyte total cell lysate stimulated with Pam3CSK4 (Pam, 10 lgmL1), or PGN from S. aureus (PGN,
20 lgmL1) plus or minus bafilomycin A1 (BafA, 100 nM) and/or MCC950 (10 lM) for 18 h (n = 3). Lower panel: Western blot of mature
caspase-1 (p20), and b-actin, from CD14+ monocyte total cell lysate stimulated with LPS (1 lgmL1) or SAA (5 lgmL1) plus or minus
MCC950 (10 lM) and BafA (100 nM) for 18 h (n = 2). (G) Western blot of caspase-1 p45, p33, p20 and p10 species, and lipidated LC3B
detected from CD14+ monocyte total lysates stimulated with LPS (1 µgmL1) plus and minus BafA, (100 nM) or biotin-YVAD-cmk (bVAD,
50 µM) for 18 h (n = 5).
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LPS (Fig. 4A). There was also a decrease in lysosomal
protease activity after LPS treatment alone (Fig. 4A),
possibly due to reduced expression of lysosomal
enzymes [23]. To explore this further, we treated pri-
mary human CD14+ monocytes with the lysomotropic
base NH4Cl alongside LPS to directly raise lysosomal
luminal pH. Cell lysates were then blotted for active
caspase-1 and lipidated LC3B, and DQ-BSA fluores-
cence was monitored 18 h after stimulation. Treatment
with 5 mM NH4Cl appeared to inhibit lysosomal activ-
ity as suggested by an increase in lipidated LC3B
(Fig. 4B), but surprisingly there was no effect on DQ-
BSA fluorescence, suggesting that V-ATPases could
still restore lysosomal acidity over a long stimulation
period (Fig. 4C). Importantly, there was no effect on
LPS-induced caspase-1 activity (Fig. 4B). We then
tested other disruptors of lysosomal activity. Chloride
levels profoundly influence lysosomal function and the
broad spectrum Cl channel inhibitor NPPB is known
to modulate lysosomal activity via altering the lyso-
some luminal Cl [24]. NPPB (50 µM) strongly inhib-
ited the lysosomal DQ-BSA signal (Fig. 4C), but also
inhibited flux through the autophagy pathway since
there was no enhancement of lipidated LC3B in con-
trast to what we observed with other lysosome disrupt-
ing agents (Fig. 4D). Mutations in Niemann–Pick type
C 1 (NPC1) cause lysosomal storage disease due to
defective lysosomal cholesterol export and can be
chemically mimicked by U18666A [25,26]. Treatment
of primary human CD14+ monocytes with U18666A
(20 µM) plus LPS inhibited lysosomal activity shown
by a significant reduction in DQ-BSA fluorescence
(Fig. 4C) and by an increase in lipidated LC3B
Fig. 3. V-ATPase inhibition enhances NLRP3-dependent caspase-1
maturation in THP-1 cells. (A) Western blot of mature caspase-1
(p20), NLRP3, and b-actin from undifferentiated WT or NLRP3 KO
THP-1 total cell lysates stimulated with LPS (1 µgmL1) plus and
minus bafilomycin A1 (BafA, 100 nM) for 18 h (n = 3). (B) IL-1b
release measured by ELISA, and (C) cell death measured by LDH
release, from WT and NLRP3 KO THP-1 cell supernatants stimulated
with LPS (1 µgmL1) plus and minus BafA (100 nM) for 18 h (n = 6
and n = 4 respectively). (D) Western blot of mature caspase-1 (p20)
and b-actin from undifferentiated WT THP-1 cells stimulated with
LPS (1 µgmL1) plus and minus nigericin (Nig, 10 µM) in the
absence or presence of extracellular KCl (20 mM) for 18 h. Nigericin
was added at the last hour of stimulation (n = 3). (E) Western blot of
mature caspase-1 (p20) and b-actin from undifferentiated or PMA
(250 nM, 16 h) differentiated WT THP-1 total cell lysates stimulated
with LPS (1 µgmL1) plus and minus BafA (100 nM) for 18 h (n = 2).
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 determined by
a two-way ANOVA with Sidak’s post hoc comparison. Values shown
are the mean  SEM.
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(Fig. 4D). However, neither NPPB, nor U18666A
treatment enhanced LPS-induced caspase-1 activation
induced by extracellular LPS in human monocytes
(Fig. 4D), although they were previously described to
inhibit canonical NLRP3 inflammasome activation
[27,28]. These data suggest that the effects of bafilomy-
cin A1 on the NLRP3 pathway occur independent of
lysosomal pH.
Fig. 4. The effects of V-ATPase inhibition on NLRP3 are independent of lysosomal pH. (A) Representative images and relative fluorescent
intensity quantification (emission at 620 nm) from CD14 + monocytes treated with LPS (1 µgmL1) or bafilomycin A1 (BafA, 100 nM) in the
presence of 10 µgmL1 DQ-BSA Red for 18 h (Scale bar 25 µM, n = 4). (B) Western blot of mature caspase-1 (p20), lipidated LC3B, and b-
actin from CD14+ monocyte total cell lysate stimulated with LPS (1 µgmL1) plus BafA (100 nM) or NH4Cl (5 mM) for 18 h (n = 4). (C)
Relative fluorescence intensity of CD14+ monocytes treated with or without LPS plus NH4Cl (5 mM), NPPB (50 lM), U18666A (20 lM) in the
presence of 10 µgmL1 DQ-BSA Red for 18 h (n = 6). (D) Western blot of mature caspase-1 (p20), lipidated LC3B, and b-actin from
CD14 + monocyte total cell lysate stimulated with BafA (100 nM), NPPB (50 lM) or U18666A (U186, 20 lM) for 18 h (n = 3). (E) Western
blot of NLRP3, ASC, pro-caspase-1 (p45), mature caspase-1 (p20), caspase-8, RIPK1 and FADD from CD14+ monocyte total cell lysate
stimulated with LPS (1 µgmL1) plus and minus BafA (100 nM) for 18h (n = 6). (F) Densitometry of RIPK1 in samples stimulated as shown
in (E) (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 was determined using one-sample t test versus hypothetical value of 100% (in A,C) or by
a one-way ANOVA with Sidak’s post hoc comparison (F). Values shown are the mean  SEM.
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Unlike the canonical NLRP3 pathway, the alterna-
tive NLRP3 inflammasome pathway is dependent on a
protein complex consisting of RIPK1-FADD-caspase-
8 upstream of NLRP3 [8]. Since these experiments
involved prolonged treatment (18 h) with LPS and
bafilomycin A1, we examined the expression levels of
RIPK1, FADD, and caspase-8, as well as components
of the NLRP3 inflammasome, to test if effects on
expression of these regulators could explain the effects
of bafilomycin A1. Neither treatment with LPS or
bafilomycin A1 altered the expression of ASC, cas-
pase-1, caspase-8 or FADD (Fig. 4E). LPS induced
the expression of NLRP3, but this was unaffected by
co-treatment of bafilomycin A1 (Fig. 4E). Levels of
RIPK1 were increased by LPS alone and were further
enhanced by bafilomycin A1 co-treatment (Fig. 4E,F).
These data suggest the possibility that bafilomycin A1
may potentiate the upstream RIPK1-FADD-caspase-8
signalling leading to enhanced activation of NLRP3.
Discussion
Understanding the regulation of the NLRP3 inflamma-
some has attracted widespread interest, in part, due to
its contribution to disease [2]. However, understanding
NLRP3 is complicated due to the multiple pathways
regulating its activity. Proposed pathways include the
canonical, the noncanonical, and the alternative
NLRP3 pathways [2]. The alternative NLRP3 pathway
has been described in primary human monocytes and
is characterized by an independence from K+ efflux
and ASC speck formation [8]. As innate immune cells
in the human blood, monocytes possess a unique
capacity to activate the alternative inflammasome and
secrete IL-1b in response to extracellular LPS. The
levels of IL-1b released by primary monocytes in
response to LPS alone are relatively small compared
to the classical two step activation pathway [7], but
could circulate and act systemically to modulate dis-
ease progression [29]. Here we report that the V-
ATPase may be an important regulator of the NLRP3
inflammasome in primary human monocytes. The
specific V-ATPase inhibitor bafilomycin A1 has been
used previously to inhibit canonical two step NLRP3
activation caused by lysosomal dysfunction and partic-
ulate matter [8,30,31]. Here we demonstrated that inhi-
bition of V-ATPase activity with bafilomycin A1 led
to the exacerbation of NLRP3 inflammasome activa-
tion in human monocytes in response to LPS. Thus
these data suggested regulation of the NLRP3 path-
way by the V-ATPase.
The data presented here strongly suggest that the V-
ATPase acted independently of lysosomal pH in
regulating the NLRP3 inflammasome and point to a
regulation of RIPK1. In addition to lysosomal pH, the
V-ATPase is also reported to be important for nutrient
sensing, including glucose and amino acids, by mTOR
(mammalian target of rapamycin) and AMP-activated
protein kinase which happens at the cytosolic surface
of lysosomes [13,32]. Understanding how V-ATPase
and RIPK1 interact is a subject for future study.
Several sub-units of the V-ATPase have been shown
to be specifically targeted by pathogenic effectors to
enhance the intracellular survival of bacteria [33–35].
Therefore, enhanced NLRP3 activation in monocytes
by V-ATPase inhibition may represent an enhanced
host-response to certain intracellular pathogens.
Whether pathogen infection synergistically alters the
monocyte inflammasome responses in human sepsis by
endotoxin and V-ATPase inhibition requires further
investigation.
In summary, we report the discovery that the V-
ATPase is an important regulator of the NLRP3
inflammasome pathway in human monocytes. This dis-
covery furthers our understanding of NLRP3 biology
and is an important consideration for the development




Inflammasome activators used include: LPS from
Escherichia coli O26:B6 (L2654; Sigma, Poole, UK), nigeri-
cin sodium salt (N7143; Sigma), synthetic Pam3CSK4 (tlrl-
pms; Invivogen, Toulouse, France), PGN from S. aureus
(77140; Sigma), and recombinant human Apo- SAA (300-13;
Peprotech, London, UK). Pharmacological agents used
include: Bafilomyicin A1 (B1793; Sigma), Concanamycin A
(B2091, Axxora, Exeter, UK), MCC950 (PZ0280; Sigma),
biotin-YVAD-cmk (bYVAD) (AS-60841; Anaspec, Fre-
mont, CA, USA), NPPB (0593; Tocris, Bristol, UK),
U18666A (U3633; Sigma), DQ-BSA Red (D12051; Thermo
Fisher, Waltham, MA, USA), and DMSO (472301; Sigma).
Cell-permeable Control and TRIF blocking peptide were
obtained from Invivogen (tlrl-pitrif). Primary antibodies
were used targeting: NLRP3 (Cryo2, AG-20B-0014-C100;
Adipogen, San Diego, CA, USA), human IL-1b (AF-201;
R&D, Abingdon, UK), ASC (AL177, AG-25B-0006-C100;
Adipogen), Caspase-1 p45 and p10 EPR16883 (ab179515;
Abcam, Cambridge, UK), human mature Caspase-1 p20
D7F10 (#3866; CST), IL-1b (AF-201-NA; R&D), LC3B
(ab48394; Abcam), Caspase-8 (ab108333; Abcam), RIPK1
(#3493; Cell Signaling Technology, Waltham, MA, USA),
FADD (#2782; Cell Signaling Technology) and HRP-b-actin
(A3854; Sigma).
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Cell culture and stimulation
Human PBMCs were obtained with consent from healthy
human donors (National Health Service Blood and Trans-
plant, Manchester, UK), with full ethical approval from
the University Research Ethics Committee (UREC) at the
University of Manchester (ref. 2017-2551-3945). Briefly,
fresh human PBMCs were separated from leukocyte cones
using Ficoll reagent (Thermo Fisher) at 400 g for 40 min at
RT with zero deceleration. PBMCs were washed three
times with filtered PBS containing 0.5% BSA and 2 mM
EDTA (MACs buffer). Human CD14 monocytes were then
positively selected from PBMCs using magnetic CD14
MicroBeads and LS columns (Miltenyi Biotec, Woking,
UK) according to the manufacturer’s instructions. PBMCs
and CD14 + monocytes were counted before being resus-
pended in RPMI-1640 medium (Sigma) supplemented with
1% (vol/vol) FBS, 100 UmL1 penicillin, 100 lgmL1
streptomycin and 2 mM L-glutamine.
Human wild-type (WT) and NLRP3 KO THP-1 cells were
cultured in RPMI-1640 medium supplemented with 10% (vol/
vol) FBS, 100 UmL1 penicillin, and 100 lgmL1 strepto-
mycin and 2 mM L-glutamine. For THP-1 cell stimulation,
suspension cells were counted and resuspended in RPMI-1640
containing 1% (vol/vol) FBS. For differentiation of the THP-
1 cells, THP-1 monocytes were seeded at 1 9 106 cells per mL
on flat-bottom plates in the presence of PMA (250 nM for
20 h). PMA-differentiated THP-1 cells were then stimulated
with indicated treatments. Cultured THP-1 cells between pas-
sages 3–15 were used for experiments.
For inflammasome stimulation, cells were stimulated
with 1 µgmL1 LPS in the presence or absence of drug
with DMSO vehicle control for 18 h. For human IL-1b
ELISA and LDH release, culture plates containing mono-
cytes were placed on ice immediately after stimulation and
centrifuged at 600 g for 5 min at 4 °C. Cell supernatants
were collected and analysed using human IL-1b ELISA kit
(R&D) and CytoTox 96 cytotoxicity assay (Promega,
Southampton, UK) on a Synergy HT plate reader (BioTek,
Winooski, VT, USA). For TRIF inhibition experiments,
primary human monocytes were incubated with Control or
TRIF blocking peptide (50 lM) for 2 h before stimulation.
R&D ELISA kits were also used to quantify levels of
IL-1a, IL-6, and TNF-a according to manufacturer’s
instructions. For total protein western blotting, both cell
supernatant and lysates (total lysates) were collected and
lysed in 59 SDS-containing Laemmli buffer and heated at
95 °C for 5 min.
Western blotting
Total cell lysates were separated by standard Tris-glycine
SDS/PAGE and then transferred onto Polyvinylidene fluo-
ride membranes (Millipore, Watford, UK) at 25 V using a
semidry Trans-Blot Turbo system (Bio-Rad). Membranes
were blocked in 2.5% (wt/vol) BSA or 5% skimmed milk
in PBS containing 0.1% (vol/vol) Tween 20 (PBST) before
overnight incubation at 4 °C with indicated primary anti-
bodies. Membranes were then labelled with HRP-conju-
gated secondary antibodies (Dako, Stockport, UK) and
visualized with Amersham ECL prime detection reagent
(GE Healthcare, Amersham, UK). Western blot images
were captured digitally using a G:Box Chemi XX6 (Syn-
gene, Cambridge, UK). Densitometry was performed
against the corresponding b-actin blot using FIJI (Image J,
NIH, Bethesda, MD, USA).
ASC oligomerization assay
Human primary CD14+ monocytes, or WT and NLRP3
KO THP-1 cells were seeded into 12-well plates at a density
of 1 9 106 cells per mL. Following LPS stimulation
(1 µgmL1, 18 h), cells were directly lysed in the well by
the addition of 1% (vol/vol) Nonidet P-40 (NP-40) or Tri-
ton X100 with 19 protease inhibitor cocktail (Millipore).
Cell lysates were separated into NP-40 or Triton 9100 sol-
uble fraction and insoluble fraction using differential cen-
trifugation at 6800 g for 20 min at 4 °C. The soluble
fraction of cell lysates was subsequently boiled in 1X
Laemmli buffer and used for western blotting, whereas the
NP-40 or Triton 9100 insoluble pellets were chemically
cross-linked with 2 mM DSS (Thermo Fisher) in PBS for
30 min at RT. DSS-cross-linked pellets were spun down at
6800 g for 20 min and then heated at 95 °C for 5 min in
19 Laemmli buffer for SDS/PAGE.
Immunofluorescence
For immunostaining, CD14+ monocytes were adhered to
sterilized 13 mm thick glass coverslips at a density of
1 9 106 cells per mL using serum-free RPMI and incubated
at 37 °C for 15 min in 5% CO2 [36]. After removing
serum-free RPMI, adherent cells were then stimulated in
1% (vol/vol) FBS RPMI-1640 medium containing respec-
tive treatments for 18 h. Cells were washed with cold PBS
once and fixed with 4% (wt/vol) paraformaldehyde for
20 min. Fixed cells were blocked and permeabilized with
1% (wt/vol) BSA, 0.1% (vol/vol) Triton X-100, and 0.05%
(vol/vol) Tween 20 in PBS. Anti-ASC antibodies (Adi-
pogen) were incubated in 1% (wt/vol) BSA, 0.3% (vol/vol)
Triton X-100 in PBS overnight at 4 °C. Coverslips were
then washed three times with PBS before incubation with
anti-rabbit AlexaFluor 594 secondary antibodies (Thermo
Fisher) for 1 h at RT. After a further three washes with
PBS, cells were stained with 1 µgmL1 DAPI. Samples
were washed three times before being mounted in Prolong
Gold (Thermo Fisher). Images were captured using a 209
objective on a Zeiss Axioimager D2 upright microscope
(Oberkochen, Germany) and subsequently processed and
analysed using IMAGEJ software.
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Lysosomal activity
Freshly isolated human CD14+ monocytes were resus-
pended in serum-free RPMI and seeded in 96-well clear
bottom plates (Greiner Bio-One, Stonehouse, UK) at 106
cells per mL for 15 min at 37 °C in 5% CO2. Serum-free
RPMI was replaced with 1% (vol/vol) FBS RPMI-1640
supplemented with or without 10 µgmL1 DQ-BSA Red
(Thermo Fisher). Cells were stimulated for 18 h with indi-
cated treatments and imaged live using a 209 objective on
an Incucyte ZOOM System (Essen BioScience, Royston,
UK). Absorbance at 620 nm emission wavelength per field
of view was quantified, and absorbance threshold was set
using no DQ-BSA control.
Quantification and Statistical analysis
Human donors are represented in individual data points. n
represents experiments performed on individual human
donors or different passage THP-1 cells per independent
experiment. Data are presented as mean values  SEM.
Equal variance and normality were assessed with Levene’s test
and the Shapiro–Wilk test, respectively, and appropriate
transformations were applied when necessary. Statistical anal-
yses were carried out using GRAPHPAD PRISM 8 (San Diego, CA,
USA). Data with multiple groups were analysed using
matched one-way or two-way ANOVA followed by Sidak’s
post hoc analysis. Accepted levels of significance were
*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
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